Drug Profile
Emibetuzumab - Eli Lilly and Company
Alternative Names: Anti-c-MET-monoclonal-antibody-Eli-Lilly; c-MET monoclonal antibody - Eli Lilly; c-MET-mAb-Eli-Lilly; cMET antibody - Eli Lilly; LA-480; LY-2875358Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gastric cancer; Non-small cell lung cancer
- Phase I/II Cancer
Most Recent Events
- 08 Sep 2021 Phase II development is ongoing in Non-small cell lung cancer (Combination therapy, Metastatic disease, First-line therapy) in United Kingdom, Denmark, France, Germany, Italy, Netherlands, Spain, South Korea and Taiwan (NCT01897480)
- 24 Jan 2018 Eli Lilly completes a phase I/II trial in Cancer (Late stage disease, Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT02082210)
- 06 Jun 2017 Safety and efficacy data from the phase II Balise trial in Non-small cell lung cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)